Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 91 - a unique biologic for the treatment of rare NovoSevenⓇ bleeding disorders NovoSevenⓇ reported sales DKK billion 3.0 2.5 2.0 1.5 1.0 0.5 0.0 Q3 2011 1 CAGR for 5-year period changing diabetes CAGR¹ (0.1%) • . Key NovoSeven® properties Product characteristics: powder and solvent for solution for intravenous injection, available in multiple doses, stable at room temperature MixProⓇ administration system launched in 2013 Indications: treatment of spontaneous and surgical bleedings in: • Haemophilia A or B patients with inhibitors • Acquired haemophilia • Congenital FVII deficiency Q3 2016 • Glanzmann's thrombasthenia² 2 Only indicated in Europe and the US novo nordisk

View entire presentation